10003205 J Clin Psychiatry / Document Archive

Psychiatrist.com Home    Keyword Search

Close [X]

Search Our Sites

Enter search terms below (keywords, titles, authors, or subjects). Then select a category to search and press the Search button. All words are assumed to be required. To search for an exact phrase, put it in quotes. To exclude a term, precede it with a minus sign (-).

Keyword search:

Choose a category:

Choosing the appropriate category will greatly improve your chances of finding the best match.

All files at our sites: J Clin Psychiatry, Primary Care Companion, CME Institute, and MedFair

Search materials from our journals:

Abstracts from The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements

PDFs of the full text of The Journal of Clinical Psychiatry, 1996–present, both regular issues and supplements (Net Society Platinum [paid subscribers])

PDFs of the full text of The Primary Care Companion to The Journal of Clinical Psychiatry, 1999–present

Search CME offerings:

CME Institute, including CME from journals , supplements, and Web activities for instant CME credit (Net Society Gold [registered users]); also includes information about our CME program

CME activities from regular issues of The Journal of Clinical Psychiatry (Net Society Gold [registered users])

CME Supplements from The Journal of Clinical Psychiatry (Net Society Gold [registered users])

 

The article you requested is

Is There a Common Resilience Mechanism Underlying Antidepressant Drug Response? Evidence From 2848 Patients.

J Clin Psychiatry 2007;68:1195-1205
Copyright 2007 Physicians Postgraduate Press, Inc.

To view this item, select one of the options below.

  1. NONSUBSCRIBERS
    1. Purchase this PDF for $40
      If you are not a paid subscriber, you may purchase the PDF.
      (You'll need the free Adobe Acrobat Reader.)
    2. Subscribe
      Receive immediate full-text access to JCP. You can subscribe to JCP print + online for $166 individual.
      JCP's 75th AnniversaryCelebrate!
      Celebrate JCP's 75th Anniversary with a special online-only subscription price of $75.
  2. PAID SUBSCRIBERS
    1. Activate
      If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
    2. Sign in
      As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
  1. Did you forget your password?

Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send an email

| 54.211.201.65

Objectives: Timing issues of antidepressant drug response are of major clinical relevance, given our current inability to predict when a particular patient will respond to a particular treatment.

Method: We detailed the time characteristics of recovery in a study of 2848 patients (diagnosed according to DSM-III-R/DSM-IV criteria as having major depressive disorder or major depressive episode) who were treated with 7 different antidepressants and placebo. A 2-dimensional cure model was used to disentangle the 2 central aspects of psychotropic drug response: the proportion of patients in whom a therapeutic response is induced (incidence) and the time to onset of improvement (latency). Random-effects models were applied to quantify unexplained heterogeneity. Patients were recruited between June 1982 and May 1998.

Results: Our analyses yielded no indication for a delayed onset of antidepressant drug response. Rather, we found highly individual time characteristics of recovery along with a continuous distribution of the time spans to onset of improvement under treatment with all active compounds and placebo. The mean ± SD time to onset of improvement was 13 ± 1 days and to response was 19 ± 1 days. Effective antidepressants appeared to trigger and maintain conditions necessary for recovery from the disorder. Odds-ratio analysis based on a random-effects model revealed that early improvers were at least 3 times more likely to become sustained responders with a pooled OR of 9.25, 95% CI = 7.79 to 10.98.

Conclusions: Affectively ill patients are likely to possess a common, biological, "resilience"-like component that largely controls recovery from depression. Once triggered, recovery appears to follow a pattern similar to the course observed with placebo, despite marked pharmacologic differences of the triggers. These findings may pave the way for new classes of psychotropic drugs specifically designed to support health-oriented processes underlying the natural resilience of patients.